



2021 VIRTUAL FORUMS

CASCADIA'S LIFE SCIENCES LEADING IN THE GLOBAL FIGHT AGAINST COVID-19

FEBRUARY 2, 2021

9:00AM – 11:00AM

Researchers, life sciences companies and health care professionals in the Cascadia Innovation Corridor have played a leading role in the global fight against COVID-19. The development of treatments, diagnostics, vaccine technology and the coordination of vaccine trials continues to advance at a rapid pace due in part to local leadership and collaboration across the Pacific Northwest. The virtual forum, ***Cascadia's life sciences leading in the global fight against COVID-19***, will be hosted by the Co-Chairs of the Cascadia Innovation Corridor Sub-Committee on Life Sciences, **Lesley Esford, Ph.D.**, Principal, Bio2Strategy and **David Grossman, M.D., M.P.H.**, National Senior Medical Director for Community Health, Kaiser Permanente.

AGENDA

9:00am	Welcome	Greg D'Avignon , President and CEO, Business Council of British Columbia Governor Chris Gregoire , CEO, Challenge Seattle
9:10 am	Agenda Overview	Lesley Esford, Ph.D. , Principal, Bio2Strategy, and Co-Chair, Cascadia Innovation Corridor Sub-Committee on Life Sciences
9:15 am	Panel: <i>SARS-CoV2 testing development and implementation</i>	Charissa Fotinos, M.D. , Deputy Chief Medical Officer, Washington State Health Care Authority Sue Paish, Q.C. , CEO, Canada's Digital Technology Supercluster and Co-Chair, Canada's COVID-19 Testing and Screening Expert Advisory Panel Emily Turner, Ph.D., M.Sc.P.H. , Senior Program Officer, Global Health, Bill and Melinda Gates Foundation Moderator: David Grossman, M.D., M.P.H. , National Senior Medical Director for Community Health, Kaiser Permanente, Co-Chair, Cascadia Innovation Corridor Sub-Committee on Life Sciences

10:03 am	Panel: <i>Cascadia leadership in vaccine and treatment development</i>	Carl Hansen, Ph.D. , CEO, AbCellera Biologics Pieter Cullis, Ph.D. , Scientific Director and CEO, NanoMedicines Innovation Network Lisa Jackson, M.D., M.P.H. , Senior Investigator, Kaiser Permanente Washington Health Research Institute Moderator: Larry Corey, M.D. , President and Director Emeritus, Fred Hutch
10:45 am	Closing Remarks	Governor Christine Gregoire and Greg D'Avignon

SPEAKERS



Lesley Esford, Ph.D., Principal, Bio2Strategy and Co-Chair, Cascadia Innovation Corridor Sub-Committee on Life Sciences

Dr. Lesley Esford, Principal of Bio2Strategy, received her Ph.D. in Microbiology and Immunology from UBC and has spent many years in academia, industry and government in positions supporting the growth of the Life Sciences sector. Since 2006, she has worked as an ITA for NRC-IRAP, helping over 100 entrepreneurs developing a wide array of products and services, at every stage of the innovation process, from concept to commercialization.

Lesley is a Kauffman Fellow, which is a Silicon Valley-based international leadership program for venture capitalists and innovators.



David Grossman, M.D., M.P.H., National Senior Medical Director for Community Health, Kaiser Permanente and Co-Chair, Cascadia Innovation Corridor Sub-Committee on Life Sciences

David Grossman, M.D., M.P.H., is a senior investigator, a pediatrician at Kaiser Permanente Washington, and a senior medical director for the Washington Permanente Medical Group.

Dr. Grossman's research includes evaluating interventions to improve the uptake of preventive services. He has an extensive background in injury prevention and control, as well as Native American health disparities research.

Dr. Grossman is immediate past Chair of the U.S. Preventive Services Task Force (USPSTF) Sponsored by the Agency for Healthcare Research and Quality (AHRQ), the USPSTG is an

www.connectcascadia.com

[#connectcascadia](https://twitter.com/connectcascadia)

independent panel of experts that reviews clinical evidence and provides recommendations on a range of preventive services. Dr. Grossman served as a member of the USPSTF 2008 until March 2018.

In his role as a senior associate medical director for Washington Permanente Medical Group, Dr. Grossman assists customers with population strategy for some of the organization's largest purchasers. He also collaborates with teams in Kaiser Permanente Washington's public policy and community benefit programs to help improve the health and well-being of members and the community.

www.kpwashingtonresearch.org



Charissa Fotinos, M.D., Deputy Chief Medical Officer, Washington State Health Care Authority

Dr. Charissa Fotinos is the Deputy Chief Medical Officer and Director of Behavioral Health Integration at Washington State's Health Care Authority. In this position, she provides support to both the Health Care Authority and the Department of Social and Health Services in support of the Apple Health/Medicaid programs. Her primary focus at this time is on improving access to and the care of persons with substance use and mental health disorders.

Dr. Fotinos has focused her career on providing care to and improving the systems of care for underserved populations. She has helped to develop mobile medical programs to deliver health care to persons living homeless and has spent a number of years providing care in the field for persons living homeless.

She holds a Master of Science degree in evidence-based health care from Oxford University, Kellogg College, in England and is a Clinical Associate Professor at the University of Washington in the Department of Family Medicine.

Prior to her current position, Dr. Fotinos was the Chief Medical Officer for Public Health Seattle-King County.

Dr. Fotinos is board certified in Family and Addiction Medicine. Before joining Seattle-King County, she was a physician-faculty member at the Providence Family Medicine Residency in Seattle, Washington.

hca.wa.gov

www.connectcascadia.com

[#connectcascadia](https://twitter.com/connectcascadia)



Sue Paish, Q.C., CEO, Canada's Digital Technology Supercluster and Co-Chair, Canada's COVID-19 Testing and Screening Expert Advisory Panel

Sue is the CEO of the Digital Technology Supercluster, which is developing, deploying, and scaling made-in-Canada digital solutions to address some of the biggest challenges in society and industry and driving business growth and our country's global competitiveness through a collaborative innovation model.

Sue chairs the Boards of the CORIX Group of Companies and Canexia Health and serves on the Board of Own the Podium and Stemcell Technologies. She is the Co-Chair of Canada's COVID-19 Testing and Screening Expert Advisory Panel, a member of the Expert Panel on Housing Supply and Affordability and the Government of Canada's COVID-19 Supply Council.

www.digitalsupercluster.ca



Emily Turner, Ph.D., M.Sc.P.H., Senior Program Officer, Global Health and COVID-19 Task Team Lead, Diagnostics, Bill and Melinda Gates Foundation

Dr. Emily Turner is Senior Program Officer on the Global Health Innovative Technology Solutions team and is serving as Task Force Lead for COVID-19 Diagnostics at the Bill and Melinda Gates foundation.

Prior to joining the foundation in 2017, Emily's research focused on technology development, including next-generation sequencing, ultrasensitive proteomics, and single-cell methods. She served as the Director of Research and Development at the Northwest Genomics Center and led the bioinformatics team implementing genomics-based clinical diagnostics at the University of Washington Lab Medicine. Following her public health studies, she joined the LSHTM Ebola Anthropology Platform as a consulting researcher on the impact of humanitarian crises on national health systems.

Emily earned a Ph.D. in Chemistry from the University of Washington, and an M.Sc. in Public Health from the London School of Hygiene and Tropical Medicine.

www.gatesfoundation.org

www.connectcascadia.com

[#connectcascadia](https://twitter.com/connectcascadia)



Larry Corey, M.D., President and Director Emeritus, Fred Hutch

Dr. Larry Corey is an internationally renowned expert in virology, immunology and vaccine development, and the former President and Director of the Fred Hutchinson Cancer Research Center. His research focuses on herpes viruses, HIV, the novel coronavirus and other viral infections, including those associated with cancer. He is Principal Investigator of the HIV Vaccine Trials Network, or HVTN, which conducts studies of HIV vaccines at over 80 clinical trials sites in 16 countries on five continents. Under his leadership, the HVTN has become the model for global, collaborative research. Dr. Corey is also the Principal Investigator of the Fred Hutch-based operations center of the COVID-19 Prevention Network (CoVPN) and co-leads the Network's COVID-19 vaccine testing pipeline. The CoVPN is carrying out the large Operation Warp Speed portfolio of COVID-19 vaccines and monoclonal antibodies intended to protect people from COVID-19.

Dr. Corey is a member of the U.S. National Academy of Medicine and the American Academy of Arts and Sciences and was the recipient of the Parran Award for his work in HSV-2, the American Society of Microbiology Cubist Award for his work on antivirals, and the University of Michigan Medical School Distinguished Alumnus Award. He is one of the most highly cited biomedical researchers in the last 20 years and is the author, coauthor, or editor of over 1000 scientific publications.

fredhutch.org



Pieter Cullis, Ph.D., Scientific Director and CEO, NanoMedicines Innovation Network and Professor, Department of Biochemistry and Molecular Biology, University of British Columbia

Dr. Cullis and co-workers have been responsible for fundamental advances in the design and development of nanomedicines employing lipid nanoparticle (LNP) technology for cancer therapies and gene therapies. This work has contributed to five drugs that have been approved by regulatory agencies in the U.S., Europe, and Canada.

Dr. Cullis has co-founded ten biotechnology companies that now employ over 300 people, has published over 350 scientific articles and is an inventor on over 60 patents. He also co-founded the Centre for Drug Research and Development, a Centre of Excellence for the Commercialization of Research (now AdMare) in 2004, the Personalized Medicine Initiative (PMI) in 2012 and the NanoMedicines Innovation Network in 2019. Dr. Cullis was elected a Fellow of the Royal Society of Canada in 2004 and was also awarded the Prix Galien, Canada's premier prize for achievements in pharmaceutical R&D, in 2011.

www.connectcascadia.com

[#connectcascadia](https://twitter.com/connectcascadia)

Two recently approved drugs that are enabled by LNP delivery systems devised by Dr. Cullis, members of his UBC laboratory and colleagues in the companies he has co-founded deserve special emphasis. The first is Onpattro which was approved by the U.S. FDA in August 2018 to treat the previously fatal hereditary condition transthyretin-induced amyloidosis (hATTR). Onpattro is the first RNAi drug to receive regulatory approval. The second is BNT162b2, the COVID-19 vaccine developed by Pfizer/BioNTech that has now been approved in Canada, the U.S., the U.K., and Europe. It is anticipated that more than 1.3B doses of BNT162b2 will be administered worldwide in 2021.

www.nanomedicines.ca



Carl Hansen, Ph.D., CEO, AbCellera Biologics

Dr. Carl Hansen works at the interface of engineering, biology, and computation. He is the Co-Founder and CEO of AbCellera, a technology company that discovered the world's first antibody therapy authorized to treat mild to moderate COVID-19. His significant contributions to society are represented in 90 peer-reviewed manuscripts and abstracts, 75+ patent applications, 8 commercial products, two of B.C.'s fastest-growing biotechnology companies, and nearly 300 new jobs in B.C.

www.abcellera.com



Lisa Jackson, M.D., M.P.H., Senior Investigator, Kaiser Permanente Washington Health Research Institute

Dr. Lisa Jackson is Senior Investigator at Kaiser Permanente Washington Health Research Institute. She is an internist with the Washington Permanente Medical Group and an infectious disease epidemiologist. As Principal Investigator for one of 10 Vaccine & Treatment Evaluation Units that the National Institutes of Health sponsors nationwide, she leads the Phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH, which was the first to test a COVID-19 vaccine beginning in March 2020. She is also leading Phase 3 clinical trials of COVID-19 vaccines developed by Moderna and by Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson. In addition, she serves as Kaiser Permanente Washington Health Research Institute's Principal Investigator in the CDC's Vaccine Safety Datalink Project, which conducts ongoing research on the safety of vaccines after they are distributed to the public.

www.kpwashingtongresearch.org

www.connectcascadia.com

[#connectcascadia](https://twitter.com/connectcascadia)



Governor Christine Gregoire, CEO, Challenge Seattle, Former Governor, Washington State and Co-Chair, Cascadia Innovation Corridor

Christine Gregoire is the CEO for Challenge Seattle. Challenge Seattle is an alliance of CEOs from 17 of the region’s largest private-sector employers who work together to ensure the Greater Seattle area continues to thrive as one of the most vibrant, innovative, and globally competitive regions in the world.

Previously, Chris served for two terms as Governor of the State of Washington with a \$32B biennial budget and over 60,000 employees. She led historical investment in strategically significant infrastructure, an historic number of trade missions, reformed the foster care system to protect children, and was among the first to lead in health care reform. Prior to becoming Governor, Chris served for three terms as Washington State’s Attorney General.

Chris is a member and former Chair of the Fred Hutch Cancer Research Center, Member of the National Bipartisan Governor’s Council. She served as Chair of the National Export-Import Bank Advisory Board 2013 – 2016.

www.challengeseattle.com



Greg D’Avignon, President and CEO, Business Council of British Columbia, Co-Chair, Cascadia Innovation Corridor

Greg D’Avignon is the President and CEO of the Business Council of B.C., a 260-member driven policy and advocacy organization comprised of the province’s leading businesses in every sector of the provincial economy and B.C.’s post-secondary institutions. A fourth generation British Columbian, Greg has held senior private and public sectors leadership positions over the last 25 years, including serving the Prime Minister of Canada.

Greg is the immediate past Chair of the B.C. Cancer Foundation and former Chair of the Canadian Breast Cancer Foundation. He is a current member of the Board of the YMCA of Greater Vancouver, the Premier’s Indigenous Business Investment Council, the B.C. Academic Health Science Network, and the Pacific Autism Family Centre Foundation.

www.bcbc.com

www.connectcascadia.com

[#connectcascadia](https://twitter.com/connectcascadia)